These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27393948)

  • 1. Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.
    Kondengaden SM; Luo LF; Huang K; Zhu M; Zang L; Bataba E; Wang R; Luo C; Wang B; Li KK; Wang PG
    Eur J Med Chem; 2016 Oct; 122():382-393. PubMed ID: 27393948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of novel histone lysine methyltransferase G9a inhibitors (part 1): molecular design based on a series of substituted 2,4-diamino-7- aminoalkoxyquinazoline by molecular-docking-guided 3D quantitative structure-activity relationship studies.
    Feng T; Wang H; Zhang X; Sun H; You Q
    Med Chem; 2014 Jun; 10(4):426-40. PubMed ID: 24151879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
    Chen WL; Wang ZH; Feng TT; Li DD; Wang CH; Xu XL; Zhang XJ; You QD; Guo XK
    Bioorg Med Chem; 2016 Nov; 24(22):6102-6108. PubMed ID: 27720557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.
    Liu F; Chen X; Allali-Hassani A; Quinn AM; Wigle TJ; Wasney GA; Dong A; Senisterra G; Chau I; Siarheyeva A; Norris JL; Kireev DB; Jadhav A; Herold JM; Janzen WP; Arrowsmith CH; Frye SV; Brown PJ; Simeonov A; Vedadi M; Jin J
    J Med Chem; 2010 Aug; 53(15):5844-57. PubMed ID: 20614940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
    Pappano WN; Guo J; He Y; Ferguson D; Jagadeeswaran S; Osterling DJ; Gao W; Spence JK; Pliushchev M; Sweis RF; Buchanan FG; Michaelides MR; Shoemaker AR; Tse C; Chiang GG
    PLoS One; 2015; 10(7):e0131716. PubMed ID: 26147105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delineating the active site architecture of G9a lysine methyltransferase through substrate and inhibitor binding mode analysis: a molecular dynamics study.
    Ramya Chandar Charles M; Hsieh HP; Selvaraj Coumar M
    J Biomol Struct Dyn; 2019 Jul; 37(10):2581-2592. PubMed ID: 30047835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening.
    Charles MRC; Mahesh A; Lin SY; Hsieh HP; Dhayalan A; Coumar MS
    Biochimie; 2020 Jan; 168():220-230. PubMed ID: 31756401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properly substituted analogues of BIX-01294 lose inhibition of G9a histone methyltransferase and gain selective anti-DNA methyltransferase 3A activity.
    Rotili D; Tarantino D; Marrocco B; Gros C; Masson V; Poughon V; Ausseil F; Chang Y; Labella D; Cosconati S; Di Maro S; Novellino E; Schnekenburger M; Grandjenette C; Bouvy C; Diederich M; Cheng X; Arimondo PB; Mai A
    PLoS One; 2014; 9(5):e96941. PubMed ID: 24810902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
    Lenstra DC; Al Temimi AHK; Mecinović J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1234-1238. PubMed ID: 29519735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase.
    Kubicek S; O'Sullivan RJ; August EM; Hickey ER; Zhang Q; Teodoro ML; Rea S; Mechtler K; Kowalski JA; Homon CA; Kelly TA; Jenuwein T
    Mol Cell; 2007 Feb; 25(3):473-81. PubMed ID: 17289593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of G9a inhibitor BIX‑01294 acting on U251 glioma cells.
    Guo AS; Huang YQ; Ma XD; Lin RS
    Mol Med Rep; 2016 Nov; 14(5):4613-4621. PubMed ID: 27748874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The methyltransferase G9a regulates HoxA9-dependent transcription in AML.
    Lehnertz B; Pabst C; Su L; Miller M; Liu F; Yi L; Zhang R; Krosl J; Yung E; Kirschner J; Rosten P; Underhill TM; Jin J; Hébert J; Sauvageau G; Humphries RK; Rossi FM
    Genes Dev; 2014 Feb; 28(4):317-27. PubMed ID: 24532712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294.
    Chang Y; Zhang X; Horton JR; Upadhyay AK; Spannhoff A; Liu J; Snyder JP; Bedford MT; Cheng X
    Nat Struct Mol Biol; 2009 Mar; 16(3):312-7. PubMed ID: 19219047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substrate specificity and kinetic mechanism of mammalian G9a histone H3 methyltransferase.
    Patnaik D; Chin HG; Estève PO; Benner J; Jacobsen SE; Pradhan S
    J Biol Chem; 2004 Dec; 279(51):53248-58. PubMed ID: 15485804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of protoberberine alkaloids as novel histone methyltransferase G9a inhibitors by structure-based virtual screening.
    Chen J; Lin X; Park KJ; Lee KR; Park HJ
    J Comput Aided Mol Des; 2018 Sep; 32(9):917-928. PubMed ID: 30171419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
    Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; Vilas-Zornoza A; Ugarte A; de Miguel I; Miranda E; Garate L; Fraga M; Santamarina P; Fernandez Perez R; Ordoñez R; Sáez E; Roa S; García-Barchino MJ; Martínez-Climent JA; Liu Y; Wu W; Xu M; Prosper F; Oyarzabal J
    J Med Chem; 2018 Aug; 61(15):6518-6545. PubMed ID: 29953809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
    Yokoyama M; Chiba T; Zen Y; Oshima M; Kusakabe Y; Noguchi Y; Yuki K; Koide S; Tara S; Saraya A; Aoyama K; Mimura N; Miyagi S; Inoue M; Wakamatsu T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Yokosuka O; Iwama A
    Oncotarget; 2017 Mar; 8(13):21315-21326. PubMed ID: 28423509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological and transcriptional inhibition of the G9a histone methyltransferase suppresses proliferation and modulates redox homeostasis in human microvascular endothelial cells.
    Wojtala M; Macierzyńska-Piotrowska E; Rybaczek D; Pirola L; Balcerczyk A
    Pharmacol Res; 2018 Feb; 128():252-263. PubMed ID: 29113759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G9a - An Appealing Antineoplastic Target.
    Chen WL; Sun HP; Li DD; Wang ZH; You QD; Guo XK
    Curr Cancer Drug Targets; 2017; 17(6):555-568. PubMed ID: 27174055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma.
    Ren A; Qiu Y; Cui H; Fu G
    Biochem Biophys Res Commun; 2015 Mar; 459(1):10-7. PubMed ID: 25634693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.